iCardiac Announces Award of a Global Phase III Cardiac Safety Study

Share Article

iCardiac to Centralize ECG Data from Clinical Sites on 4 Continents

iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that it has been awarded a centralized ECG services contract for a global multi-site Phase III study. The study will be conducted leveraging iCardiac’s next generation solutions for cost-effective centralization of digital ECG data as well as COMPAS technology platform for ECG data analysis.

“This study award is a milestone achievement for iCardiac as we continue successfully expanding our services in the global ECG market,” said Sasha Latypova, Executive Vice President. “Drug cardiac safety is rapidly evolving with tougher standards imposed by the regulators. We are proud to deliver the next generation of advanced ECG services for improving precision, accuracy and resource efficiency of global cardiac safety studies.”

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc., provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of Highly Automated QT evaluation as well as controlling for autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac’s services are supported by the COMPAS technology platform which maximizes the precision and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies. This suite of tools, which complies with the FDA’s ICH E14 QT/QTc guidance for Through QT Studies (TQT), was originally developed and validated at the University of Rochester’s Heart Research Follow Up Program (HRFUP), as well as in Pfizer’s Research and Development programs. iCardiac’s analytics have been used for over a decade in support of clinical trials.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alexandra Latypova
Visit website